Majumdar A, Hoang L, Loc LT, Srivastava P, Ramamurthy C, Chakravorty R, Nandanwar YS, Rashmi MD, Mayekar RV, Sridhar J, Divekar GH, John J. A Multicenter Phase IV Study to Investigate the Immunogenicity of Recombinant Human Follicle-Stimulating Hormone and Its Impact on Clinical Outcomes in Females Undergoing Controlled Ovarian Stimulation.
J Hum Reprod Sci 2019;
12:303-309. [PMID:
32038080 PMCID:
PMC6937766 DOI:
10.4103/jhrs.jhrs_33_19]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Revised: 06/25/2019] [Accepted: 11/01/2019] [Indexed: 11/29/2022] Open
Abstract
CONTEXT
Therapeutic proteins can cause immune responses, which may have clinical implications.
AIMS
The aim of the study was to assess the immunogenicity of recombinant human follicle-stimulating hormone (r-hFSH), when used for controlled ovarian stimulation (COS).
SETTINGS AND DESIGN
Prospective, multicenter study conducted at reproductive medicine clinics in India and Vietnam.
MATERIALS AND METHODS
A total of 285 women, aged 20-40 years, undergoing 354 COS cycles for either intrauterine insemination (IUI) or in vitro fertilization (IVF) were studied. The primary outcome measure was the incidence of development of anti-drug antibodies (ADA) and their neutralization potential. Other outcome measures were follicle development, dose and duration of r-hFSH, positive serum pregnancy test, clinical pregnancy, cycle cancellation, and adverse events (AEs).
STATISTICAL ANALYSIS USED
A sample size of 250 was planned. Descriptive statistics are presented.
RESULTS
Four patients tested positive for ADA after r-hFSH administration at different time points; all of them tested negative, subsequently. None were found to have neutralization potential. The mean dose and duration of r-hFSH were 816 IU and 8.1 days in IUI and 2183 IU and 9.5 days in IVF, respectively. The serum and clinical pregnancy rates were 12.4% and 11.6% in IUI and 32.7% and 29.9% in IVF cycles, respectively. Seven AEs were reported, including two cases of ovarian hyperstimulation syndrome; two AEs were judged to be serious.
CONCLUSIONS
The tested r-hFSH has very low immunogenic potential and did not lead to the development of neutralizing antibodies. The overall efficacy and safety of the drug were in-line with existing literature data, and no specific clinical impact of immunogenicity could be identified.
Collapse